CYP26B1 inhibitor compounds and their methods of use

JP2026519569APending Publication Date: 2026-06-1616380026·CANADA INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
16380026·CANADA INC
Filing Date
2024-05-29
Publication Date
2026-06-16

Smart Images

  • Figure 2026519569000991
    Figure 2026519569000991
  • Figure 2026519569000992
    Figure 2026519569000992
  • Figure 2026519569000993
    Figure 2026519569000993
Patent Text Reader

Abstract

This disclosure provides compounds for inhibiting CYP26B1 and pharmaceutically acceptable salts thereof. Aspects of this disclosure include methods of using the compounds to treat diseases or disorders including, but not limited to, skin disorders, cancer, neurological disorders, ectopic ossification (HO), fibrodysplasia ossificans progressive (FOP), multiple osteochondroma, and eye diseases including meibomian gland dysfunction and dry eye disease.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A compound of formula (I), 【Chemistry 1】 During the ceremony, A, (1) - (CR １ R ２ ) ｍ -X-(CR ３ R ４ ) - and R １ and R ２ These are H, Halo, and C, each independent of the others. １－６ Selected from alkyl groups, R ３ and R ４ are each independently selected from H, halo, and C １－６ alkyl, or R ３ and R ４ together with the carbon atom to which they are attached form C ３－６ cycloalkyl, m is 0 or 1, X is S, SO, SO ２ Selected from , O, and NH, - (CR １ R ２ ) ｍ -X-(CR ３ R ４ ) - (2) - (CR ６ R ７ ) ｎ -CR ８ R ９ - (CR １０ R １１ ) ｐ - and R ６ and R ７ Each of them independently, H or C １－６ It is alkyl, R ８ and R ９ Each of them independently becomes a Haro or C １－６ Alkyl or R ８ and R ９ However, along with the carbon atoms to which they are bonded, C ３－６ Forming a cycloalkyl group, R １０ and R １１ Each of them independently, H or C １－６ It is alkyl, n is 0 or 1, p is 0 or 1, -(CR ６ R ７ ) ｎ -CR ８ R ９ - (CR １０ R １１ ) ｐ - （３） 【Chemistry 2】 And B is C ３－６ It is a cycloalkyl, 【Transformation 3】 、 (4)-CH ２ CHR １２ - and R １２ However, C １－６ It is alkyl, -CH ２ CHR １２ - (5)-CHR １３ CH ２ - and R １３ However, C １－６ Alkyl, -CHR １３ CH ２ -, and (6)-CH ２ CH ２ CH ２ -, selected from, 【Chemistry 4】 is the following part Y １ Y ２ Y ３ Y ４ Y ５ Y ６ Y ７ Y ８ Y ９ Y １０ Y １１ Y １２ Y １３ Y １４ and Y １５ : 【Transformation 5】 Selected from, During the ceremony, R １４ 、R １９ 、R ２３ 、R ２７ 、R ３９ 、R ４３ 、R ４４ 、R ４９ 、R ５３ 、R ５６ 、R ５９ 、and R ６５ are each independently H, halo, cyano, -OH, C １－６ alkyl, C ３－６ cycloalkyl, 3- to 6-membered heterocycloalkyl, -C(O)NH ２ 、-C(O)NHC １－３ alkyl, -C(O)NHC ３－６ cycloalkyl, -C(O)N(C １－３ alkyl) ２ 、-C(O)N(C １－３ alkyl)(C ３－６ cycloalkyl), -NH ２ 、-NHC １－６ alkyl, -NHC ３－６ cycloalkyl, -N(C １－３ alkyl)(C １－６ alkyl), -N(C １－３ alkyl)(C ３－６ cycloalkyl), -NHC(O)C １－３ alkyl, -NHC(O)C ３－６ cycloalkyl, -N(C １－３ alkyl)(C(O)C １－３ alkyl), -N(C １－３ alkyl)(C(O)C ３－６ cycloalkyl), -OC １－６ alkyl, -OC ３－６ cycloalkyl, -O(3- to 6-membered heterocycloalkyl), -SC １－６ alkyl, -SC ３－６ cycloalkyl, -S(3- to 6-membered heterocycloalkyl), -S(O) ２ C １－６ alkyl, -S(O) ２ C ３－６ cycloalkyl, and -S(O) ２ (3- to 6-membered heterocycloalkyl), and are selected from C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, R １５ , R ２０ , R ２４ , R ２８ , R ３１ , R ３６ , R ４０ , R ４５ , R ６０ , R ６２ , R ６６ , and R ６９ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－６ Cycloalkyl, 3-6 member heterocycloalkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, R １６ , R ２５ , R ２９ , R ３２ , R ３７ , R ４１ , R ４６ , R ５０ , R ５４ , R ６３ , R ６７ , and R ７０ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－６ Cycloalkyl, 3-6 member heterocycloalkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, R １７ , R ２１ , R ３０ , R ３３ , R ３８ , R ４２ , R ４７ , R ５１ , R ５７ , R ６４ , R ６８ , and R ７１ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－６ Cycloalkyl, 3-6 member heterocycloalkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, Each R ａ These independently consist of F, cyano, -OH, and C. ３－４ Cycloalkyl, 3-5 member heterocycloalkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, Each R ｂ These independently form F, cyano, -OH, oxo (=O), and C. １－３ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－３ Alkyl, -OC １－３ It is optionally substituted with alkyl, Each R ｃ These independently form F, cyano, -OH, oxo (=O), and C. １－３ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－３ Alkyl, -OC １－３ It is optionally substituted with alkyl, R １８ , R ２２ , R ２６ , R ３４ , R ３５ , R ４８ , R ５２ , R ５５ , R ５８ , and R ６１ Each of these independently produces H, -OH, and C. １－６ Selected from alkyl groups, C １－６ Alkyl groups are independently F, cyano, -OH, and -OC. １－３ Alkyl, -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -SH, and -SC １－３ It is optionally substituted with 1 to 3 substituents selected from alkyl groups. L is a single bond, 【Transformation 6】 And, During the ceremony, R ７２ However, H or -CH ３ And, R ７３ However, H or -CH ３ And, R ７４ and R ７５ Each of these independently produces H, F, and -CH. ３ Selected from, X １ However, O, S, or NR ７６ And R ７６ However, H or -CH ３ And, R ７７ However, equation (a), equation (b), or equation (c): 【Transformation 7】 It is, During the ceremony, X ２ , X ３ , X ４ , X ５ , and X ６ Each is independently selected from C and N, and X ２ , X ３ , X ４ , X ５ , and X ６ At least one of them is N, R ７８ However, it is absent, H, or F. R ７９ , R ８０ , and R ８１ Each of these is either absent or H, halo, cyano, -OH, C １－６ Alkyl, C ３－１０ Cycloalkyl, 3-6 member heterocycloalkyl, phenyl, 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ｄ The substituents are optionally substituted, C ３－１０ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and 1 to 2 R groups are 3 to 6-membered heterocycloalkyl groups. ｆ The substituents are optionally substituted, and phenyl is present in 1-2 R groups. ｇ The substituents are optionally substituted, and 1 to 2 R groups are 5 to 10-membered heteroaryl groups. ｈ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ｄ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-2 R ｆ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-2 R groups. ｆ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-2 R ｆ The substituents are optionally substituted, R ８２ However, it is absent, H, or F. (a), (b), and (c) below: (a) R ７８ However, being F, (b) R ７９ , R ８０ , and R ８１ At least one of the C is substituted with halo, cyano, -OH, or any other. １－６ Alkyl, optionally substituted C ３－１０ Cycloalkyl, optionally substituted 3-6 member heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), the -OC which is optionally substituted １－６ Alkyl, optionally substituted -OC ３－６ Cycloalkyl, optionally substituted -O (3-6 member heterocycloalkyl), optionally substituted -SC １－６ Alkyl, optionally substituted -SC ３－６ Cycloalkyl, optionally substituted -S (3-6 member heterocycloalkyl), optionally substituted -S(O) ２ C １－６ Alkyl, optionally substituted -S(O) ２ C ３－６ Cycloalkyl and optionally substituted -S(O) ２ (Selected from 3-6 member heterocycloalkyl groups), (c) R ８２ However, there exists at least one of the following conditions: F, R ７７ is the one in formula (a) above, and R ８１ If R is a substituted phenyl, ８１ Two -OC １－３ Not substituted with alkyl, R ８３ However, it is H or F, R ８４ , R ８５ , and R ８６ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－１０ Cycloalkyl, 3-6 member heterocycloalkyl, phenyl, 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ｄ The substituents are optionally substituted, C ３－１０ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and 1 to 2 R groups are 3 to 6-membered heterocycloalkyl groups. ｆ The substituents are optionally substituted, and phenyl is present in 1-2 R groups. ｇ The substituents are optionally substituted, and 1 to 2 R groups are 5 to 10-membered heteroaryl groups. ｈ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ｄ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-2 R ｆ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-2 R groups. ｆ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-2 R ｆ The substituents are optionally substituted, R ８７ However, it is H or F, (d), (e), and (f) below: (d) R ８３ However, being F, (e) R ８４ , R ８５ , and R ８６ At least one of the C is substituted with halo, cyano, -OH, or any other. １－６ Alkyl, optionally substituted C ３－１０ Cycloalkyl, optionally substituted 3-6 member heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), the -OC which is optionally substituted １－６ Alkyl, optionally substituted -OC ３－６ Cycloalkyl, optionally substituted -O (3-6 member heterocycloalkyl), optionally substituted -SC １－６ Alkyl, optionally substituted -SC ３－６ Cycloalkyl, optionally substituted -S (3-6 member heterocycloalkyl), optionally substituted -S(O) ２ C １－６ Alkyl, optionally substituted -S(O) ２ C ３－６ Cycloalkyl and optionally substituted -S(O) ２ (Selected from 3-6 member heterocycloalkyl groups), (f) R ８７ However, at least one of the following exists: F, or R ８３ H is R ８４ H is R ８７ H is R ８５ and R ８６ However, along with the ring atom to which they are bonded, C ４－６ Forming a cycloalkyl or 4-6 member heterocycloalkyl, C ４－６ Each cycloalkyl group is independently C １－６ It is optionally substituted with 1 to 4 alkyl substituents, and each of the 4 to 6-membered heterocycloalkyl groups is independently C １－６ It is optionally substituted with 1 to 4 substituents selected from alkyl and oxo (=O) groups. X ７ However, it is C or N, X ８ , X ９ , X １０ , and X １１ Each is independently selected from C, N, S, and O, and X ７ , X ８ , X ９ , X １０ , and X １１ At least one of them is N, S, or O, R ８８ , R ８９ , R ９０ , and R ９１ Each of these is either absent or H, halo, cyano, -OH, C １－６ Alkyl, C ３－１０ Cycloalkyl, 3-6 member heterocycloalkyl, phenyl, 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ｄ The substituents are optionally substituted, C ３－１０ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and 1 to 2 R groups are 3 to 6-membered heterocycloalkyl groups. ｆ The substituents are optionally substituted, and phenyl is present in 1-2 R groups. ｇ The substituents are optionally substituted, and 1 to 2 R groups are 5 to 10-membered heteroaryl groups. ｈ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ｄ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-2 R ｆ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-2 R groups. ｆ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-2 R ｆ The substituents are optionally substituted, R ８８ , R ８９ , R ９０ , and R ９１ At least one of the C is substituted with halo, cyano, -OH, or any other. １－６ Alkyl, optionally substituted C ３－１０ Cycloalkyl, optionally substituted 3-6 member heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), the -OC which is optionally substituted １－６ Alkyl, optionally substituted -OC ３－６ Cycloalkyl, optionally substituted -O (3-6 member heterocycloalkyl), optionally substituted -SC １－６ Alkyl, optionally substituted -SC ３－６ Cycloalkyl, optionally substituted -S (3-6 member heterocycloalkyl), optionally substituted -S(O) ２ C １－６ Alkyl, optionally substituted -S(O) ２ C ３－６ Cycloalkyl and optionally substituted -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), Each R ｄ These independently consist of F, cyano, -OH, and C. ３－４ Cycloalkyl, 3-5 member heterocycloalkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, R ｅ Each of these independently consists of F, cyano, -OH, oxo (=O), and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－６ Alkyl, -OC １－３ It is optionally substituted with alkyl, Each R ｆ These independently form F, cyano, -OH, oxo (=O), and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ , -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－６ Alkyl, -OC １－３ It is optionally substituted with alkyl, Each R ｇ These independently consist of F, cyano, -OH, and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ , -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, Each R ｈ These independently consist of F, cyano, -OH, and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ , -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, R ９２ However, -C(O)OH, 【Transformation 8】 Selected from, The aforementioned compound, 【Chemistry 9】 A compound of formula (I) or a pharmaceutically acceptable salt thereof that is not selected from the above.

2. The aforementioned compound, Formula (IA): 【Chemistry 10】 【change】 Selected from, where L, X, R １ , R ２ , R ３ , R ４ , R ６ , R ７ , R ８ , R ９ , R １０ , R １１ , R １２ , R １３ , R ７７ , R ９２ , m, n, p, 【Chemistry 11】 、 The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein each of and B is as defined in claim 1.

3. The aforementioned compound is a compound of formula (IA): 【Chemistry 12】 And, In the formula, L, X, R １ , R ２ , R ３ , R ４ , R ７７ , R ９２ , m, and 【Chemistry 13】 The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each of the is defined in claim 1.

4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein m is 0.

5. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein m is 1.

6. R １ and R ２ The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein each of is independently selected from H, F, and methyl.

7. X is S, SO, SO ２ A compound according to any one of claims 1 to 6, selected from , and O, or a pharmaceutically acceptable salt thereof.

8. X is S, SO, and SO ２ A compound according to any one of claims 1 to 7, selected from, or a pharmaceutically acceptable salt thereof.

9. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein X is S.

10. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein X is SO.

11. X is SO ２ The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof.

12. A compound according to any one of claims 1 to 7, wherein X is O, or a pharmaceutically acceptable salt thereof.

13. R ３ and R ４ A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein each of is independently selected from H, F, and methyl.

14. R ３ A compound according to any one of claims 1 to 13, wherein the compound is methyl, or a pharmaceutically acceptable salt thereof.

15. R ３ and R ４ A compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is methyl.

16. R ３ and R ４ A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein each of the elements is H.

17. R ３ and R ４ A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is a halo.

18. R ３ and R ４ A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is F.

19. R ３ and R ４ However, along with the carbon atoms to which they are bonded, C ３－６ A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, which forms a cycloalkyl group.

20. R ３ and R ４ The compound according to claim 19, or a pharmaceutically acceptable salt thereof, wherein they form a cyclopropyl group together with the carbon atoms to which they are bonded.

21. The aforementioned compound is a compound of formula (IB): 【Chemistry 14】 And, In the formula, L, R ６ , R ７ , R ８ , R ９ , R １０ , R １１ , R ７７ , R ９２ , n, p, and 【Chemistry 15】 The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each of the is defined in claim 1.

22. A compound according to any one of claims 1, 2, and 21, or a pharmaceutically acceptable salt thereof, wherein n is 1 and p is 0.

23. R ８ and R ９ A compound according to any one of claims 1, 2, and 21-22, or a pharmaceutically acceptable salt thereof, wherein each is independently selected from F and methyl.

24. R ８ and R ９ A compound according to any one of claims 1, 2, and 21-23, wherein each of the compounds is methyl, or a pharmaceutically acceptable salt thereof.

25. R ８ and R ９ A compound according to any one of claims 1, 2, and 21-22, or a pharmaceutically acceptable salt thereof, wherein each of these is a halo.

26. R ８ and R ９ A compound according to any one of claims 1, 2, and 21-23, wherein each of these is F, or a pharmaceutically acceptable salt thereof.

27. R ８ and R ９ However, along with the carbon atoms to which they are bonded, C ３－６ A compound according to any one of claims 1, 2, and 21-22, or a pharmaceutically acceptable salt thereof, which forms a cycloalkyl group.

28. R ８ and R ９ The compound according to claim 27, or a pharmaceutically acceptable salt thereof, wherein the carbon atoms to which they are bonded form a cyclopropyl group.

29. R ６ and R ７ A compound according to any one of claims 1, 2, and 21-28, or a pharmaceutically acceptable salt thereof, wherein each is independently selected from H and methyl.

30. R ６ and R ７ A compound according to any one of claims 1, 2, and 21-29, wherein each of the elements is H, or a pharmaceutically acceptable salt thereof.

31. The aforementioned compound is a compound of formula (IC): 【Chemistry 16】 And, In the formula, L, R ７７ R ９２ , 【Chemistry 17】 、 The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each of and B is as defined in claim 1.

32. A compound according to any one of claims 1, 2, and 31, or a pharmaceutically acceptable salt thereof, wherein B is selected from cyclopropyl, cyclobutyl, and bicyclo[1.1.1]pentane.

33. The aforementioned compound is a compound of formula (IE): [Chemistry 18] ,or Compounds of formula (IF): 【Chemistry 19】 And, In the formula, L, R １２ , R １３ , R ７７ , R ９２ , and 【Chemistry 20】 The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each of the is defined in claim 1.

34. R １２ and R １３ The compounds according to claims 1, 2, and 33, or pharmaceutically acceptable salts thereof, wherein each of them is methyl.

35. The aforementioned compound is a compound of formula (IG): 【Chemistry 21】 And, In the formula, L, R ７７ , R ９２ , and 【Chemistry 22】 The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each of the is defined in claim 1.

36. R １４ 、R １９ 、R ２３ 、R ２７ 、R ３９ 、R ４３ 、R ４４ 、R ４９ 、R ５３ 、R ５６ 、R ５９ 、and R ６５ are each independently selected from H, halo, cyano, C １－６ alkyl, and C ３－６ cycloalkyl, R １５ 、R ２０ 、R ２４ 、R ２８ 、R ３１ 、R ３６ 、R ４０ 、R ４５ 、R ６０ 、R ６２ 、R ６６ 、and R ６９ are each independently selected from H, halo, cyano, C １－６ alkyl, and C ３－６ cycloalkyl, R １６ 、R ２５ 、R ２９ 、R ３２ 、R ３７ 、R ４１ 、R ４６ 、R ５０ 、R ５４ 、R ６３ 、R ６７ 、and R ７０ are each independently selected from H, halo, cyano, C １－６ alkyl, and C ３－６ cycloalkyl, R １７ 、R ２１ 、R ３０ 、R ３３ 、R ３８ 、R ４２ 、R ４７ 、R ５１ 、R ５７ 、R ６４ 、R ６８ 、and R ７１ are each independently selected from H, halo, cyano, C １－６ alkyl, and C ３－６ cycloalkyl, R １８ , R ２２ , R ２６ , R ３４ , R ３５ , R ４８ , R ５２ , R ５５ , R ５８ , and R ６１ Each of them independently, H or C １－６ A compound according to any one of claims 1 to 35, which is alkyl, or a pharmaceutically acceptable salt thereof.

37. R １４ 、R １９ 、R ２３ 、R ２７ 、R ３９ 、R ４３ 、R ４４ 、R ４９ 、R ５３ 、R ５６ 、R ５９ 、およびR ６５ are each independently selected from H, F, Br, cyano, C １－３ alkyl, and cyclopropyl, R １５ 、R ２０ 、R ２４ 、R ２８ 、R ３１ 、R ３６ 、R ４０ 、R ４５ 、R ６０ 、R ６２ 、R ６６ 、およびR ６９ are each independently selected from H, F, Br, cyano, C １－３ alkyl, and cyclopropyl, R １６ 、R ２５ 、R ２９ 、R ３２ 、R ３７ 、R ４１ 、R ４６ 、R ５０ 、R ５４ 、R ６３ 、R ６７ 、およびR ７０ are each independently selected from H, F, Br, cyano, C １－３ alkyl, and cyclopropyl, R １７ 、R ２１ 、R ３０ 、R ３３ 、R ３８ 、R ４２ 、R ４７ 、R ５１ \R ５７ 、R ６４ 、R ６８ 、およびR ７１ are each independently selected from H, F, Br, cyano, C １－３ alkyl, and cyclopropyl, R １８ 、R ２２ 、R ２６ 、R ３４ , R ３５ , R ４８ , R ５２ , R ５５ , R ５８ , and R ６１ A compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein each of the atoms is independently H or methyl. 【Request Item 38】 【Chemistry 23】 However, part Y １ : 【Chemistry 24】 And R １４ , R １５ , R １６ , R １７ , and R １８ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37.

39. R １４ H is R １５ is H, F, cyano, or methyl, and R １６ is H or F, R １７ H is R １８ The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein is H.

40. R １４ , R １５ , R １６ , R １７ , and R １８ The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein each of the is H.

41. R １４ H is R １５ F is R １６ H is R １７ H is R １８ The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein is H.

42. R １４ H is R １５ H is R １６ F is R １７ H is R １８ The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein is H. 【Request Item 43】 【Chemistry 25】 However, part Y ２ : 【Chemistry 26】 And R １９ , R ２０ , R ２１ , and R ２２ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37.

44. R １９ H is R ２０ is H, F, cyano, or methyl, and R ２１ H is R ２２ The compound according to claim 43, or a pharmaceutically acceptable salt thereof, wherein is H.

45. R １９ , R ２０ , R ２１ , and R ２２ The compound according to claim 43, or a pharmaceutically acceptable salt thereof, wherein each of the is H. 【Request Item 46】 【Chemistry 27】 However, part Y ３ : 【Chemistry 28】 And R ２３ , R ２４ , R ２５ , and R ２６ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37.

47. R ２３ , R ２４ , R ２５ , and R ２６ The compound according to claim 46, or a pharmaceutically acceptable salt thereof, wherein each of the is H. [Request Item 48] [Chemistry 29] However, part Y ４ : 【Transformation 30】 And R ２７ , R ２８ , R ２９ , and R ３０ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37.

49. R ２７ , R ２８ , R ２９ , and R ３０ The compound according to claim 48, or a pharmaceutically acceptable salt thereof, wherein each of the is H. 【Request Item 50】 【Chemistry 31】 However, part Y ５ : 【Chemistry 32】 And R ３１ , R ３２ , R ３３ , and R ３４ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 51】 【Chemistry 33】 However, part Y ６ : 【Transformation 34】 And R ３５ , R ３６ , R ３７ , and R ３８ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 52】 【Chemistry 35】 However, part Y ７ : 【Transformation 36】 And R ３９ , R ４０ , R ４１ , and R ４２ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 53】 【Chemistry 37】 However, part Y ８ : 【Transformation 38】 And R ４３ , R ４４ , R ４５ , R ４６ , R ４７ , and R ４８ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 54】 【Chemistry 39】 However, part Y ９ : 【Chemistry 40】 And R ４９ , R ５０ , R ５１ , and R ５２ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37.

55. R ４９ , R ５０ , R ５１ and R ５２ The compound according to claim 54, or a pharmaceutically acceptable salt thereof, wherein each of the is H. 【Request Item 56】 【Chemistry 41】 However, part Y １０ : 【Chemistry 42】 And R ５３ , R ５４ , and R ５５ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 57】 【Chemistry 43】 However, part Y １１ : 【Chemistry 44】 And R ５６ , R ５７ , and R ５８ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 58】 【Chemistry 45】 However, part Y １２ : 【Chemistry 46】 And R ５９ , R ６０ , and R ６１ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 59】 【Chemistry 47】 However, part Y １３ : 【Chemistry 48】 And R ６２ , R ６３ , and R ６４ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. [Request Item 60] [Chemistry 49] However, part Y １４ : [Transformation 50] And R ６５ , R ６６ , R ６７ , and R ６８ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37. 【Request Item 61】 【Chemistry 51】 However, part Y １５ : 【Chemistry 52】 And R ６９ , R ７０ , and R ７０ A compound according to any one of claims 1 to 37, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1, 36, or 37.

62. L is a single bond, 【Chemistry 53】 And R ７２ A compound according to any one of claims 1 to 61, wherein H is present, or a pharmaceutically acceptable salt thereof.

63. A compound according to any one of claims 1 to 62, wherein L is a single bond, or a pharmaceutically acceptable salt thereof.

64. R ７７ but, 【Chemistry 54】 Selected from, R ８４ , R ８５ , and R ８６ A compound according to any one of claims 1 to 63, or a pharmaceutically acceptable salt thereof, wherein each of the compounds is as defined in claim 1.

65. R ７７ but, 【Transformation 55】 And R ８６ The compound according to claim 64, or a pharmaceutically acceptable salt thereof, as defined in claim 1.

66. R ７７ but, 【Transformation 56】 And R ８６ However, C １－６ Alkyl, C ３－１０ Cycloalkyl, -SC １－６ Alkyl, -OC １－６ Alkyl, halo, -OH, -OC ３－６ Cycloalkyl, -NHC(O)C １－６ Selected from alkyl, 3-6 member heterocycloalkyl, and 5-10 member heteroaryl, C １－６ Each alkyl group independently consists of halo, cyano, -OH, and -C(O)NH ２ , -C(O)OH, and C ３－６ It is optionally substituted with 1 to 3 substituents selected from cycloalkyl groups, C ３－１０ Each cycloalkyl group is independently cyano and C １－６ It is optionally substituted with one or two substituents selected from alkyl groups, -OC １－６ Each alkyl group is optionally substituted with 1 to 3 substituents that are independently halo, and each 3 to 6-membered heterocycloalkyl group is independently C １－６ The compound according to claim 65, or a pharmaceutically acceptable salt thereof, optionally substituted with one or two alkyl substituents.

67. R ７７ but, 【Chemistry 57】 Selected from, R ８１ A compound according to any one of claims 1 to 63, or a pharmaceutically acceptable salt thereof, as defined in claim 1.

68. R ７７ but, 【Transformation 58】 And R ８１ The compound according to claim 67, or a pharmaceutically acceptable salt thereof, as defined in claim 1.

69. R ８１ However, C １－６ Alkyl, C ３－１０ Cycloalkyl, -SC １－６ Alkyl, -OC １－６ Alkyl, halo, -OH, -OC ３－６ Cycloalkyl, -NHC(O)C １－６ Selected from alkyl, 3-6 member heterocycloalkyl, and 5-10 member heteroaryl, C １－６ Each alkyl group independently consists of halo, cyano, -OH, and -C(O)NH ２ , -C(O)OH, and C ３－６ It is optionally substituted with 1 to 3 substituents selected from cycloalkyl groups, C ３－１０ Each cycloalkyl group is independently cyano and C １－６ It is optionally substituted with one or two substituents selected from alkyl groups, -OC １－６ Each alkyl group is optionally substituted with 1 to 3 substituents that are independently halo, and each 3 to 6-membered heterocycloalkyl group is independently C １－６ The compound according to claim 67 or 68, or a pharmaceutically acceptable salt thereof, optionally substituted with one or two alkyl substituents.

70. R ７７ but, 【Chemistry 59】 Selected from, R ９０ A compound according to any one of claims 1 to 63, or a pharmaceutically acceptable salt thereof, as defined in claim 1.

71. R ９０ However, C １－６ Alkyl, C ３－１０ Cycloalkyl, -SC １－６ Alkyl, -OC １－６ Alkyl, halo, -OH, -OC ３－６ Cycloalkyl, -NHC(O)C １－６ Selected from alkyl, 3-6 member heterocycloalkyl, and 5-10 member heteroaryl, C １－６ Each alkyl group independently consists of halo, cyano, -OH, and -C(O)NH ２ , -C(O)OH, and C ３－６ It is optionally substituted with 1 to 3 substituents selected from cycloalkyl groups, C ３－１０ Each cycloalkyl group is independently cyano and C １－６ It is optionally substituted with one or two substituents selected from alkyl groups, -OC １－６ Each alkyl group is optionally substituted with 1 to 3 substituents that are independently halo, and each 3 to 6-membered heterocycloalkyl group is independently C １－６ The compound according to claim 70, or a pharmaceutically acceptable salt thereof, optionally substituted with one or two alkyl substituents.

72. R ７７ but, 【Transformation 60】 【change】 【change】 A compound according to any one of claims 1 to 63, selected from, or a pharmaceutically acceptable salt thereof.

73. R ７７ but, 【Chemistry 61】 A compound according to any one of claims 1 to 63, selected from, or a pharmaceutically acceptable salt thereof.

74. R ９２ The compound according to any one of claims 1 to 73, or a pharmaceutically acceptable salt thereof, wherein the compound is -C(O)OH.

75. The aforementioned compound, 【Transformation 62】 【change】 【change】 【change】 【change】 【change】 【change】 A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, selected from the above.

76. A pharmaceutical composition, A compound according to any one of claims 1 to 75 or a pharmaceutically acceptable salt thereof, A pharmaceutical composition comprising a pharmaceutically acceptable excipient.

77. It is a compound, 【Transformation 63】 A compound selected from, or a pharmaceutically acceptable salt thereof.

78. A pharmaceutical composition, A compound according to claim 77 or a pharmaceutically acceptable salt thereof, A pharmaceutical composition comprising a pharmaceutically acceptable excipient.

79. A method for inhibiting CYP26B1, CYP26B1 is a compound of formula (II), 【Chemistry 64】 During the ceremony, A, (1) - (CR １ R ２ ) ｍ -X-(CR ３ R ４ ) - and R １ and R ２ These are H, Halo, and C, each independent of the others. １－６ Selected from alkyl groups, R ３ and R ４ These are H, Halo, and C, each independent of the others. １－６ Selected from alkyl groups, or R ３ and R ４ However, along with the carbon atoms to which they are bonded, C ３－６ Forming a cycloalkyl group, m is 0 or 1, X is S, SO, SO ２ Selected from , O, and NH, - (CR １ R ２ ) ｍ -X-(CR ３ R ４ ) - (2) - (CR ６ R ７ ) ｎ -CR ８ R ９ - (CR １０ R １１ ) ｐ - and R ６ and R ７ Each of them independently, H or C １－６ It is alkyl, R ８ and R ９ Each of them independently becomes a Haro or C １－６ Alkyl or R ８ and R ９ However, along with the carbon atoms to which they are bonded, C ３－６ Forming a cycloalkyl group, R １０ and R １１ Each of them independently, H or C １－６ It is alkyl, n is 0 or 1, p is 0 or 1, -(CR ６ R ７ ) ｎ -CR ８ R ９ - (CR １０ R １１ ) ｐ - （３） 【Transformation 65】 And B is C ３－６ It is a cycloalkyl, 【Chemical Formula 66】 、 (4)-CH ２ CH ２ - (5)-CH ２ CHR １２ - and R １２ However, C １－６ It is alkyl, -CH ２ CHR １２ - (6)-CHR １３ CH ２ - and R １３ However, C １－６ Alkyl, -CHR １３ CH ２ -, and (7)-CH ２ CH ２ CH ２ -, selected from, 【Transformation 67】 is the following part Y １ Y ２ Y ３ Y ４ Y ５ Y ６ Y ７ Y ８ Y ９ Y １０ Y １１ Y １２ Y １３ Y １４ and Y １５ : 【Transformation 68】 【change】 Selected from, During the ceremony, R １４ , R １９ , R ２３ , R ２７ , R ３９ , R ４３ , R ４４ , R ４９ , R ５３ , R ５６ , R ５９ , and R ６５ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－６ Cycloalkyl, 3-6 member heterocycloalkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, R １５ , R ２０ , R ２４ , R ２８ , R ３１ , R ３６ , R ４０ , R ４５ , R ６０ , R ６２ , R ６６ , and R ６９ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－６ Cycloalkyl, 3-6 member heterocycloalkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, R １６ , R ２５ , R ２９ , R ３２ , R ３７ , R ４１ , R ４６ , R ５０ , R ５４ , R ６３ , R ６７ , and R ７０ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－６ Cycloalkyl, 3-6 member heterocycloalkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, R １７ , R ２１ , R ３０ , R ３３ , R ３８ , R ４２ , R ４７ , R ５１ , R ５７ , R ６４ , R ６８ , and R ７１ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－６ Cycloalkyl, 3-6 member heterocycloalkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ａ The substituents are optionally substituted, C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and 1 to 3 R groups are 3 to 6-membered heterocycloalkyl groups. ｃ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ａ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-3 R ｃ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-3 R groups. ｃ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ａ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｂ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-3 R ｃ The substituents are optionally substituted, Each R ａ These independently consist of F, cyano, -OH, and C. ３－４ Cycloalkyl, 3-5 member heterocycloalkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, Each R ｂ These independently form F, cyano, -OH, oxo (=O), and C. １－３ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－３ Alkyl, -OC １－３ It is optionally substituted with alkyl, Each R ｃ These independently form F, cyano, -OH, oxo (=O), and C. １－３ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－３ Alkyl, -OC １－３ It is optionally substituted with alkyl, R １８ , R ２２ , R ２６ , R ３４ , R ３５ , R ４８ , R ５２ , R ５５ , R ５８ , and R ６１ Each of these independently produces H, -OH, and C. １－６ Selected from alkyl groups, C １－６ Alkyl groups are independently F, cyano, -OH, and -OC. １－３ Alkyl, -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -SH, and -SC １－３ It is optionally substituted with 1 to 3 substituents selected from alkyl groups. L is a single bond, 【Transformation 69】 And, During the ceremony, R ７２ However, H or -CH ３ And, R ７３ However, H or -CH ３ And, R ７４ and R ７５ Each of these independently produces H, F, and -CH. ３ Selected from, X １ However, O, S, or NR ７６ And R ７６ However, H or -CH ３ And, R ７７ However, equation (a), equation (b), or equation (c): 【Transformation 70】 It is, During the ceremony, X ２ , X ３ , X ４ , X ５ , and X ６ Each is independently selected from C and N, and X ２ , X ３ , X ４ , X ５ , and X ６ At least one of them is N, R ７８ However, it is absent, H, or F. R ７９ , R ８０ , and R ８１ Each of these is either absent or H, halo, cyano, -OH, C １－６ Alkyl, C ３－１０ Cycloalkyl, 3-6 member heterocycloalkyl, phenyl, 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ｄ The substituents are optionally substituted, C ３－１０ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and 1 to 2 R groups are 3 to 6-membered heterocycloalkyl groups. ｆ The substituents are optionally substituted, and phenyl is present in 1-2 R groups. ｇ The substituents are optionally substituted, and 1 to 2 R groups are 5 to 10-membered heteroaryl groups. ｈ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ｄ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-2 R ｆ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-2 R groups. ｆ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-2 R ｆ The substituents are optionally substituted, R ８２ However, it is absent, H, or F. (a), (b), and (c) below: (a) R ７８ However, being F, (b) R ７９ , R ８０ , and R ８１ At least one of the C is substituted with halo, cyano, -OH, or any other. １－６ Alkyl, optionally substituted C ３－１０ Cycloalkyl, optionally substituted 3-6 member heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), the -OC which is optionally substituted １－６ Alkyl, optionally substituted -OC ３－６ Cycloalkyl, optionally substituted -O (3-6 member heterocycloalkyl), optionally substituted -SC １－６ Alkyl, optionally substituted -SC ３－６ Cycloalkyl, optionally substituted -S (3-6 member heterocycloalkyl), optionally substituted -S(O) ２ C １－６ Alkyl, optionally substituted -S(O) ２ C ３－６ Cycloalkyl and optionally substituted -S(O) ２ (Selected from 3-6 member heterocycloalkyl groups), (c) R ８２ However, there exists at least one of the following conditions: F, R ７７ is the one in formula (a) above, and R ８１ If R is a substituted phenyl, ８１ Two -OC １－３ Not substituted with alkyl, R ８３ However, it is H or F, R ８４ , R ８５ , and R ８６ Each of these independently represents H, halo, cyano, -OH, and C. １－６ Alkyl, C ３－１０ Cycloalkyl, 3-6 member heterocycloalkyl, phenyl, 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ｄ The substituents are optionally substituted, C ３－１０ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and 1 to 2 R groups are 3 to 6-membered heterocycloalkyl groups. ｆ The substituents are optionally substituted, and phenyl is present in 1-2 R groups. ｇ The substituents are optionally substituted, and 1 to 2 R groups are 5 to 10-membered heteroaryl groups. ｈ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ｄ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-2 R ｆ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-2 R groups. ｆ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-2 R ｆ The substituents are optionally substituted, R ８７ However, it is H or F, (d), (e), and (f) below: (d) R ８３ However, being F, (e) R ８４ , R ８５ , and R ８６ At least one of the C is substituted with halo, cyano, -OH, or any other. １－６ Alkyl, optionally substituted C ３－１０ Cycloalkyl, optionally substituted 3-6 member heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -N(C) １－３ (Alkyl) (C １－６ Alkyl), -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), the -OC which is optionally substituted １－６ Alkyl, optionally substituted -OC ３－６ Cycloalkyl, optionally substituted -O (3-6 member heterocycloalkyl), optionally substituted -SC １－６ Alkyl, optionally substituted -SC ３－６ Cycloalkyl, optionally substituted -S (3-6 member heterocycloalkyl), optionally substituted -S(O) ２ C １－６ Alkyl, optionally substituted -S(O) ２ C ３－６ Cycloalkyl and optionally substituted -S(O) ２ (Selected from 3-6 member heterocycloalkyl groups), (f) R ８７ However, at least one of the following exists: F, or R ８３ H is R ８４ H is R ８７ H is R ８５ and R ８６ However, along with the ring atom to which they are bonded, C ４－６ Forming a cycloalkyl or 4-6 member heterocycloalkyl, C ４－６ Each cycloalkyl group is independently C １－６ It is optionally substituted with 1 to 4 alkyl substituents, and each of the 4 to 6-membered heterocycloalkyl groups is independently C １－６ It is optionally substituted with 1 to 4 substituents selected from alkyl and oxo (=O) groups. X ７ However, it is C or N, X ８ , X ９ , X １０ , and X １１ Each is independently selected from C, N, S, and O, and X ７ , X ８ , X ９ , X １０ , and X １１ At least one of them is N, S, or O, R ８８ , R ８９ , R ９０ , and R ９１ Each of these is either absent or H, halo, cyano, -OH, C １－６ Alkyl, C ３－１０ Cycloalkyl, 3-6 member heterocycloalkyl, phenyl, 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), -OC １－６ Alkyl, -OC ３－６ Cycloalkyl, -O (3-6 member heterocycloalkyl), -SC １－６ Alkyl, -SC ３－６ Cycloalkyl, -S (3-6 member heterocycloalkyl), -S(O) ２ C １－６ Alkyl, -S(O) ２ C ３－６ Cycloalkyl and -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), C １－６ Alkyl groups: 1 to 3 R ｄ The substituents are optionally substituted, C ３－１０ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and 1 to 2 R groups are 3 to 6-membered heterocycloalkyl groups. ｆ The substituents are optionally substituted, and phenyl is present in 1-2 R groups. ｇ The substituents are optionally substituted, and 1 to 2 R groups are 5 to 10-membered heteroaryl groups. ｈ Substituents are optionally substituted, -OC １－６ Alkyl groups: 1 to 3 R ｄ Substituents are optionally substituted, -OC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, with -O (3-6 member heterocycloalkyl) and 1-2 R ｆ The substituent is optionally substituted, -SC １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -SC ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituents are optionally substituted, and -S (3-6 member heterocycloalkyl) is present in 1-2 R groups. ｆ The substituent is optionally substituted, -S(O) ２ C １－６ Alkyl groups: 1 to 3 R ｄ The substituent is optionally substituted, -S(O) ２ C ３－６ Cycloalkyl groups, 1 to 3 R ｅ The substituent is optionally substituted, -S(O) ２ (3-6 member heterocycloalkyl group) with 1-2 R ｆ The substituents are optionally substituted, R ８８ , R ８９ , R ９０ , and R ９１ At least one of the C is substituted with halo, cyano, -OH, or any other. １－６ Alkyl, optionally substituted C ３－１０ Cycloalkyl, optionally substituted 3-6 member heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-10 member heteroaryl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)NHC ３－６ Cycloalkyl, -C(O)N(C １－３ Alkyl) ２ , -C(O)N(C １－３ (Alkyl) (C ３－６ Cycloalkyl), -NH ２ , - NHC １－６ Alkyl, -NHC ３－６ Cycloalkyl, -NHC(O)C １－３ Alkyl, -NHC(O)C ３－６ Cycloalkyl, -N(C) １－３ Alkyl) (C(O)C １－３ Alkyl), -N(C １－３ Alkyl) (C(O)C ３－６ Cycloalkyl), the -OC which is optionally substituted １－６ Alkyl, optionally substituted -OC ３－６ Cycloalkyl, optionally substituted -O (3-6 member heterocycloalkyl), optionally substituted -SC １－６ Alkyl, optionally substituted -SC ３－６ Cycloalkyl, optionally substituted -S (3-6 member heterocycloalkyl), optionally substituted -S(O) ２ C １－６ Alkyl, optionally substituted -S(O) ２ C ３－６ Cycloalkyl and optionally substituted -S(O) ２ Selected from (3-6 member heterocycloalkyl groups), Each R ｄ These independently consist of F, cyano, -OH, and C. ３－４ Cycloalkyl, 3-5 member heterocycloalkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, R ｅ Each of these independently consists of F, cyano, -OH, oxo (=O), and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ ,-NHC(O)C １－３ Alkyl, -N(C) １－３ Alkyl)C(O)C １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－６ Alkyl, -OC １－３ It is optionally substituted with alkyl, Each R ｆ These independently form F, cyano, -OH, oxo (=O), and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ , -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, C １－６ Alkyl, -OC １－３ It is optionally substituted with alkyl, Each R ｇ These independently consist of F, cyano, -OH, and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ , -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, Each R ｈ These independently consist of F, cyano, -OH, and C. １－６ Alkyl, -C(O)C １－３ Alkyl, -C(O)OH, -C(O)OC １－３ Alkyl, -C(O)NH ２ , -C(O)NHC １－３ Alkyl, -C(O)N(C １－３ Alkyl) ２ , -NH ２ , - NHC １－３ Alkyl, -N(C) １－３ Alkyl) ２ , -OC １－３ Alkyl, -SH, and -SC １－３ Selected from alkyl groups, R ９２ However, -C(O)OH, 【Chemistry 71】 A method comprising contacting a compound of formula (II), or a pharmaceutically acceptable salt thereof, selected from the above.

80. The method according to claim 79, wherein the contact comprises administering a therapeutically effective amount of the compound of formula (II) or a pharmaceutically acceptable salt thereof to a subject requiring such contact, and the administration is effective in treating a disease or disorder of the subject.

81. The aforementioned diseases or disorders include acute promyelocytic leukemia (APL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), heterotopic ossification (including HO, trauma-induced and surgery-induced), fibrodysplasia ossificans progressive (FOP), multiple osteochondroma, vascular calcification (including those associated with chronic kidney disease (CKD)), ankylosing spondylitis, osteoarthritis, actinic keratosis, basal cell carcinoma and squamous cell carcinoma, esophageal squamous cell carcinoma, arsenic keratosis, and inflammatory acne. The method according to claim 80, selected from non-inflammatory acne, psoriasis, ichthyosis, keratosis, hyperproliferative skin disorders, photoaging, eczema, atopic dermatitis, Darier's disease, lichen planus, glucocorticoid injury, steroid atrophy, Alzheimer's disease, Parkinson's disease, autism spectrum disorder, schizophrenia and schizoaffective disorder, age-related dementia and cognitive impairment, adult T-cell leukemia / lymphoma, alopecia, atherosclerosis, and platelet abnormalities.

82. The method according to claim 80, wherein the disease or disorder is selected from heterotopic ossification (including HO, trauma-induced and surgery-induced), fibrodysplasia ossificans progressive (FOP), multiple osteochondroma, and vascular calcification (including those associated with chronic kidney disease (CKD)).

83. The method according to claim 80, wherein the disease or disorder is fibrodysplasia ossificans progressive (FOP).

84. The method according to claim 80, wherein the disease or disorder is multiple osteochondroma.

85. The aforementioned diseases or disorders include conjunctivitis, conjunctival goblet cell injury, corneal margin stem cell deficiency, ocular surface neoplasms, scarring conjunctival disorders (including Stevens-Johnson syndrome, graft-versus-host disease, trauma, chemical burns, burns, prolonged ultraviolet exposure, rosacea-induced injury, and infectious diseases (chlamydia, herpes diseases)), conjunctival keratosis disorders (including radiation exposure, chemical injury, and injury induced by topical medications), conjunctival disorders caused by vitamin A deficiency, pterygium syndrome, pinguecula, scarring pemphigoid, atopic keratoconjunctivitis, Sjögren's syndrome-related conjunctival injury, meibomian gland dysfunction, blepharitis, stye, chalazion, and eyelid neoplasia. The method according to claim 80, selected from: keratitis, dry eye disease, evaporative dry eye disease, conjunctivalization, corneal intraepithelial neoplasm, stem cell deficiency, corneal injury, chemically induced corneal injury, thermally induced corneal injury, trauma-induced corneal injury, radiation-induced corneal injury, corneal injury caused by vitamin A deficiency, Sjögren's syndrome-related corneal injury, corneal neovascularization, uveitis, fibroproliferative disorder, proliferative diabetic retinopathy, proliferative vitreoretinopathy, epiretinal membrane formation, neovascular membrane formation, age-related macular degeneration, drusen formation, and retinal detachment injury.

86. The method according to claim 80, wherein the disease or disorder is selected from conjunctivitis, conjunctival goblet cell injury, corneal margin stem cell deficiency, scarring conjunctival disorder (including chemical burns, burns, prolonged ultraviolet exposure, and rosacea-induced injury), conjunctival keratosis, conjunctival disorder caused by vitamin A deficiency, meibomian gland dysfunction, blepharitis, stye, chalazion, dry eye disease, evaporative dry eye disease, corneal injury, chemically induced corneal injury, heat-induced corneal injury, trauma-induced corneal injury, radiation-induced corneal injury, and corneal disorder caused by vitamin A deficiency.

87. The method according to claim 80, wherein the disease or disorder is meibomian gland dysfunction.

88. The method according to claim 80, wherein the disease or disorder is a dry eye disease.

89. The method according to claim 80, wherein the disease or disorder is an evaporative dry eye disease.

90. The aforementioned compound, Formula (IIA): 【Chemistry 72】 【change】 Selected from, where L, X, R １ , R ２ , R ３ , R ４ , R ６ , R ７ , R ８ , R ９ , R １０ , R １１ , R １２ , R １３ , R ７７ , R ９２ , m, n, p, 【Transformation 73】 、 The method according to any one of claims 79 to 89, wherein each of B is as defined in claim 79.

91. The aforementioned compound is a compound of formula (IIA): 【Chemistry 74】 And, In the formula, L, X, R １ , R ２ , R ３ , R ４ , R ７７ , R ９２ , m, and 【Chemistry 75】 The method according to any one of claims 79 to 90, wherein each of the is as defined in claim 79.

92. The method according to any one of claims 79 to 91, wherein m is 0.

93. The method according to any one of claims 79 to 91, wherein m is 1.

94. R １ and R ２ The method according to claim 93, wherein each is independently selected from H, F, and methyl.

95. X is S, SO, SO ２ The method according to any one of claims 79 to 94, selected from , and O.

96. X is S, SO, and SO ２ The method according to any one of claims 79 to 95, selected from the following.

97. The method according to any one of claims 79 to 96, wherein X is S.

98. The method according to any one of claims 79 to 96, wherein X is SO.

99. X is SO ２ The method according to any one of claims 79 to 96.

100. The method according to any one of claims 79 to 95, wherein X is O.

101. R ３ and R ４ The method according to any one of claims 79 to 100, wherein each is independently selected from H, F, and methyl.

102. R ３ The method according to any one of claims 79 to 101, wherein the substance is methyl.

103. R ３ and R ４ The method according to any one of claims 79 to 102, wherein each of them is methyl.

104. R ３ and R ４ The method according to any one of claims 79 to 101, wherein each of them is H.

105. R ３ and R ４ The method according to any one of claims 79 to 100, wherein each of them is a halo.

106. R ３ and R ４ The method according to any one of claims 79 to 101, wherein each of them is F.

107. R ３ and R ４ However, along with the carbon atoms to which they are bonded, C ３－６ The method according to any one of claims 79 to 100, for forming a cycloalkyl group.

108. R ３ and R ４ The method according to claim 107, wherein they form a cyclopropyl group together with the carbon atoms to which they are bonded.

109. The aforementioned compound is a compound of formula (IIB): 【Transformation 76】 And, In the formula, L, R ６ , R ７ , R ８ , R ９ , R １０ , R １１ , R ７７ , R ９２ , n, p, and 【Chemical 77】 The method according to any one of claims 79 to 90, wherein each of the is as defined in claim 79.

110. The method according to any one of claims 79 to 90 and 109, wherein n is 1 and p is 0.

111. R ８ and R ９ The method according to any one of claims 79-90 and 109-110, wherein each is independently selected from F and methyl.

112. R ８ and R ９ The method according to any one of claims 79 to 90 and 109 to 111, wherein each of them is methyl.

113. R ８ and R ９ The method according to any one of claims 79 to 90 and 109 to 110, wherein each of them is a halo.

114. R ８ and R ９ The method according to any one of claims 79 to 90 and 109 to 111, wherein each of them is F.

115. R ８ and R ９ However, along with the carbon atoms to which they are bonded, C ３－６ The method according to any one of claims 79 to 90 and 109 to 110, for forming a cycloalkyl group.

116. R ８ and R ９ The method according to claim 115, wherein they form a cyclopropyl group together with the carbon atoms to which they are bonded.

117. R ６ and R ７ The method according to any one of claims 79 to 90 and 109 to 116, wherein each is independently selected from H and methyl.

118. R ６ and R ７ The method according to any one of claims 79 to 90 and 109 to 117, wherein each of them is H.

119. The aforementioned compound is a compound of formula (IIC): 【Transformation 78】 And, In the formula, L, R ７７ R ９２ , 【Chemistry 79】 、 The method according to any one of claims 79 to 90, wherein each of B is as defined in claim 79.

120. The method according to any one of claims 79 to 90 and 119, wherein B is selected from cyclopropyl, cyclobutyl, and bicyclo[1.1.1]pentane.

121. The aforementioned compound is a compound of formula (IID): 【Chemistry 80】 And, In the formula, L, R ７７ , R ９２ , and 【Chemistry 81】 The method according to any one of claims 79 to 90, wherein each of the is as defined in claim 79.

122. The aforementioned compound is a compound of formula (IIE): 【Chemistry 82】 ,or Compounds of formula (IIF): 【Chemistry 83】 And, In the formula, L, R １２ , R １３ , R ７７ , R ９２ , and 【Chemical 84】 The method according to any one of claims 79 to 90, wherein each of the is as defined in claim 79.

123. R １２ and R １３ The method according to any one of claims 79 to 90 and 122, wherein each of is methyl.

124. The aforementioned compound is a compound of formula (IIG): 【Chemical 85】 And, In the formula, L, R ７７ , R ９２ , and 【Chemical 86】 The method according to any one of claims 79 to 90, wherein each of the is as defined in claim 79.

125. R １４ , R １９ , R ２３ , R ２７ , R ３９ , R ４３ , R ４４ , R ４９ , R ５３ , R ５６ , R ５９ , and R ６５ Each of these is independent: H, Halo, Cyano, C １－６ Alkyl and C ３－６ Selected from cycloalkyl, R １５ , R ２０ , R ２４ , R ２８ , R ３１ , R ３６ , R ４０ , R ４５ , R ６０ , R ６２ , R ６６ , and R ６９ Each of these is independent: H, Halo, Cyano, C １－６ Alkyl and C ３－６ Selected from cycloalkyl, R １６ , R ２５ , R ２９ , R ３２ , R ３７ , R ４１ , R ４６ , R ５０ , R ５４ , R ６３ , R ６７ , and R ７０ Each of these is independent: H, Halo, Cyano, C １－６ Alkyl and C ３－６ Selected from cycloalkyl, R １７ , R ２１ , R ３０ , R ３３ , R ３８ , R ４２ , R ４７ , R ５１ , R ５７ , R ６４ , R ６８ , and R ７１ Each of these is independent: H, Halo, Cyano, C １－６ Alkyl and C ３－６ Selected from cycloalkyl, R １８ , R ２２ , R ２６ , R ３４ , R ３５ , R ４８ , R ５２ , R ５５ , R ５８ , and R ６１ Each of them independently, H or C １－６ The method according to any one of claims 79 to 124, wherein the alkyl group is alkyl.

126. R １４ , R １９ , R ２３ , R ２７ , R ３９ , R ４３ , R ４４ , R ４９ , R ５３ , R ５６ , R ５９ , and R ６５ Each of these independently comprises H, F, Br, cyano, and C. １－３ Selected from alkyl and cyclopropyl, R １５ , R ２０ , R ２４ , R ２８ , R ３１ , R ３６ , R ４０ , R ４５ , R ６０ , R ６２ , R ６６ , and R ６９ Each of these independently comprises H, F, Br, cyano, and C. １－３ Selected from alkyl and cyclopropyl, R １６ , R ２５ , R ２９ , R ３２ , R ３７ , R ４１ , R ４６ , R ５０ , R ５４ , R ６３ , R ６７ , and R ７０ Each of these independently comprises H, F, Br, cyano, and C. １－３ Selected from alkyl and cyclopropyl, R １７ , R ２１ , R ３０ , R ３３ , R ３８ , R ４２ , R ４７ , R ５１ , R ５７ , R ６４ , R ６８ , and R ７１ Each of these independently comprises H, F, Br, cyano, and C. １－３ Selected from alkyl and cyclopropyl, R １８ , R ２２ , R ２６ , R ３４ , R ３５ , R ４８ , R ５２ , R ５５ , R ５８ , and R ６１ The method according to any one of claims 79 to 124, wherein each is independently H or methyl. 【Request Item 127】 【Chemistry 87】 However, part Y １ : 【Chemical 88】 And R １４ , R １５ , R １６ , R １７ , and R １８ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126.

128. R １４ H is R １５ is H, F, cyano, or methyl, and R １６ is H or F, R １７ H is R １８ The method according to claim 127, wherein is H.

129. R １４ , R １５ , R １６ , R １７ , and R １８ The method according to claim 127, wherein each of them is H.

130. R １４ H is R １５ F is R １６ H is R １７ H is R １８ The method according to claim 127, wherein is H.

131. R １４ H is R １５ H is R １６ F is R １７ H is R １８ The method according to claim 127, wherein is H. 【Request Item 132】 【Chemistry 89】 However, part Y ２ : 【Chemistry 90】 And R １９ , R ２０ , R ２１ , and R ２２ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126.

133. R １９ H is R ２０ is H, F, cyano, or methyl, and R ２１ H is R ２２ The method according to claim 132, wherein H is

134. R １９ , R ２０ , R ２１ , and R ２２ The method according to claim 132, wherein each of them is H. 【Request Item 135】 【Chemistry 91】 However, part Y ３ : 【Chemistry 92】 And R ２３ , R ２４ , R ２５ , and R ２６ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126.

136. R ２３ , R ２４ , R ２５ , and R ２６ The method according to claim 135, wherein each of them is H. 【Request Item 137】 【Chemistry 93】 However, part Y ４ : 【Chemical 94】 And R ２７ , R ２８ , R ２９ , and R ３０ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126.

138. R ２７ , R ２８ , R ２９ , and R ３０ The method according to claim 137, wherein each of them is H. 【Request Item 139】 【Chemistry 95】 However, part Y ５ : 【Chemistry 96】 And R ３１ , R ３２ , R ３３ , and R ３４ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. [Request Item 140] [Chemistry 97] However, part Y ６ : 【Chem.98】 And R ３５ , R ３６ , R ３７ , and R ３８ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 141】 【Chemistry 99】 However, part Y ７ : 【Chemistry 100】 And R ３９ , R ４０ , R ４１ , and R ４２ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 142】 【Chemistry 101】 However, part Y ８ : 【Chemical Engineering 102】 And R ４３ , R ４４ , R ４５ , R ４６ , R ４７ , and R ４８ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 143】 【Chemistry 103】 However, part Y ９ : 【Chemical 104】 And R ４９ , R ５０ , R ５１ , and R ５２ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126.

144. R ４９ , R ５０ , R ５１ and R ５２ The method according to claim 143, wherein each of them is H. 【Request Item 145】 【Chemistry 105】 However, part Y １０ : 【Chemistry 106】 And R ５３ , R ５４ , and R ５５ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 146】 【Chemistry 107】 However, part Y １１ : 【Chemistry 108】 And R ５６ , R ５７ , and R ５８ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 147】 【Chemistry 109】 However, part Y １２ : 【Chemical 110】 And R ５９ , R ６０ , and R ６１ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 148】 【Chemistry 111】 However, part Y １３ : 【Chemistry 112】 And R ６２ , R ６３ , and R ６４ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 149】 【Chemistry 113】 However, part Y １４ : 【Chemical 114】 And R ６５ , R ６６ , R ６７ , and R ６８ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126. 【Request Item 150】 【Chemistry 115】 However, part Y １５ : 【Chemistry 116】 And R ６９ , R ７０ , and R ７０ The method according to any one of claims 79 to 126, wherein each of the is defined in claim 79, 125, or 126.

151. L is a single bond, 【Chemistry 117】 And R ７２ The method according to any one of claims 79 to 150, wherein H is the case.

152. The method according to any one of claims 79 to 151, wherein L is a single bond.

153. R ７７ but, 【Chemistry 118】 Selected from, R ８４ , R ８５ , and R ８６ The method according to any one of claims 79 to 152, wherein each of the is as defined in claim 79.

154. R ７７ but, 【Chemical 119】 And R ８６ The method according to any one of claims 79 to 152, however, as defined in claim 79.

155. R ７７ but, 【Chemical 120】 And R ８６ However, C １－６ Alkyl, C ３－１０ Cycloalkyl, -SC １－６ Alkyl, -OC １－６ Alkyl, halo, -OH, -OC ３－６ Cycloalkyl, -NHC(O)C １－６ Selected from alkyl, 3-6 member heterocycloalkyl, and 5-10 member heteroaryl, C １－６ Each alkyl group independently consists of halo, cyano, -OH, and -C(O)NH ２ , -C(O)OH, and C ３－６ It is optionally substituted with 1 to 3 substituents selected from cycloalkyl groups, C ３－１０ Each cycloalkyl group is independently cyano and C １－６ It is optionally substituted with one or two substituents selected from alkyl groups, -OC １－６ Each alkyl group is optionally substituted with 1 to 3 substituents that are independently halo, and each 3 to 6-membered heterocycloalkyl group is independently C １－６ The method according to any one of claims 79 to 152, wherein the molecule is optionally substituted with one or two alkyl substituents.

156. R ７７ but, 【Chemistry 121】 Selected from, R ８１ The method according to any one of claims 79 to 152, however, as defined in claim 79.

157. R ７７ but, 【Chemistry 122】 And R ８１ The method according to claim 156, however, as defined in claim 79.

158. R ８１ However, C １－６ Alkyl, C ３－１０ Cycloalkyl, -SC １－６ Alkyl, -OC １－６ Alkyl, halo, -OH, -OC ３－６ Cycloalkyl, -NHC(O)C １－６ Selected from alkyl, 3-6 member heterocycloalkyl, and 5-10 member heteroaryl, C １－６ Each alkyl group independently consists of halo, cyano, -OH, and -C(O)NH ２ , -C(O)OH, and C ３－６ It is optionally substituted with 1 to 3 substituents selected from cycloalkyl groups, C ３－１０ Each cycloalkyl group is independently cyano and C １－６ It is optionally substituted with one or two substituents selected from alkyl groups, -OC １－６ Each alkyl group is optionally substituted with 1 to 3 substituents that are independently halo, and each 3 to 6-membered heterocycloalkyl group is independently C １－６ The method according to claim 156 or 157, wherein the molecule is optionally substituted with one or two alkyl substituents.

159. R ７７ but, 【Chemical 123】 Selected from, R ９０ The method according to any one of claims 79 to 152, however, as defined in claim 79.

160. R ９０ However, C １－６ Alkyl, C ３－１０ Cycloalkyl, -SC １－６ Alkyl, -OC １－６ Alkyl, halo, -OH, -OC ３－６ Cycloalkyl, -NHC(O)C １－６ Selected from alkyl, 3-6 member heterocycloalkyl, and 5-10 member heteroaryl, C １－６ Each alkyl group independently consists of halo, cyano, -OH, and -C(O)NH ２ , -C(O)OH, and C ３－６ It is optionally substituted with 1 to 3 substituents selected from cycloalkyl groups, C ３－１０ Each cycloalkyl group is independently cyano and C １－６ It is optionally substituted with one or two substituents selected from alkyl groups, -OC １－６ Each alkyl group is optionally substituted with 1 to 3 substituents that are independently halo, and each 3 to 6-membered heterocycloalkyl group is independently C １－６ The method according to claim 159, wherein the molecule is optionally substituted with one or two alkyl substituents.

161. R ７７ but, 【Chemistry 124】 【change】 The method according to any one of claims 79 to 152, selected from the following.

162. R ７７ but, 【Chemistry 125】 The method according to any one of claims 79 to 152, selected from the following.

163. R ９２ The method according to any one of claims 79 to 162, wherein the compound is -C(O)OH.

164. The aforementioned compound, 【Chemistry 126】 【change】 【change】 【change】 【change】 【change】 【change】 The method according to claims 79 to 90, selected from among them.

165. A method for inhibiting CYP26B1, CYP26B1, 【Chemistry 127】 【change】 A compound selected from, A method comprising contacting the salt thereof with a pharmaceutically acceptable salt.

166. The method according to claim 165, wherein the contact comprises administering a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject requiring such contact, and the administration is effective in treating a disease or disorder of the subject.

167. The aforementioned diseases or disorders include acute promyelocytic leukemia (APL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), heterotopic ossification (including HO, trauma-induced and surgery-induced), fibrodysplasia ossificans progressive (FOP), multiple osteochondroma, vascular calcification (including those associated with chronic kidney disease (CKD)), ankylosing spondylitis, osteoarthritis, actinic keratosis, basal cell carcinoma and squamous cell carcinoma, esophageal squamous cell carcinoma, arsenic keratosis, inflammatory acne, The method according to claim 166, selected from non-inflammatory acne, psoriasis, ichthyosis, keratosis, hyperproliferative skin disorders, photoaging, eczema, atopic dermatitis, Darier's disease, lichen planus, glucocorticoid injury, steroid atrophy, Alzheimer's disease, Parkinson's disease, autism spectrum disorder, schizophrenia and schizoaffective disorder, age-related dementia and cognitive impairment, adult T-cell leukemia / lymphoma, alopecia, atherosclerosis, and platelet abnormalities.

168. The method according to claim 166, wherein the disease or disorder is selected from heterotopic ossification (including HO, trauma-induced and surgery-induced), fibrodysplasia ossificans progressive (FOP), multiple osteochondroma, and vascular calcification (including those associated with chronic kidney disease (CKD)).

169. The method according to claim 166, wherein the disease or disorder is fibrodysplasia ossificans progressive (FOP).

170. The method according to claim 166, wherein the disease or disorder is multiple osteochondroma.

171. The aforementioned diseases or disorders include conjunctivitis, conjunctival goblet cell injury, corneal margin stem cell deficiency, ocular surface neoplasms, scarring conjunctival disorders (including Stevens-Johnson syndrome, graft-versus-host disease, trauma, chemical burns, burns, prolonged ultraviolet exposure, rosacea-induced injury, and infectious diseases (chlamydia, herpes diseases)), conjunctival keratosis disorders (including radiation exposure, chemical injury, and injury induced by topical medications), conjunctival disorders caused by vitamin A deficiency, pterygium syndrome, pinguecula, scarring pemphigoid, atopic keratoconjunctivitis, Sjögren's syndrome-related conjunctival injury, meibomian gland dysfunction, and blepharitis. The method according to claim 166, selected from stye, chalazion, eyelid neoplasm, keratitis, dry eye disease, evaporative dry eye disease, conjunctivitis, corneal intraepithelial neoplasm, stem cell deficiency, corneal injury, chemically induced corneal injury, thermally induced corneal injury, trauma-induced corneal injury, radiation-induced corneal injury, corneal injury caused by vitamin A deficiency, Sjögren's syndrome-related corneal injury, corneal neovascularization, uveitis, fibroproliferative disorder, proliferative diabetic retinopathy, proliferative vitreoretinopathy, epiretinal membrane formation, neovascular membrane formation, age-related macular degeneration, drusen formation, and retinal detachment injury.

172. The method according to claim 166, wherein the disease or disorder is selected from conjunctivitis, conjunctival goblet cell injury, corneal margin stem cell deficiency, scarring conjunctival disorders (including chemical burns, burns, prolonged ultraviolet exposure, and rosacea-induced injuries), conjunctival keratosis, conjunctival disorders caused by vitamin A deficiency, meibomian gland dysfunction, blepharitis, stye, chalazion, dry eye disease, evaporative dry eye disease, corneal injury, chemically induced corneal injury, heat-induced corneal injury, trauma-induced corneal injury, radiation-induced corneal injury, and corneal disorders caused by vitamin A deficiency.

173. The method according to claim 166, wherein the disease or disorder is meibomian gland dysfunction.

174. The method according to claim 166, wherein the disease or disorder is a dry eye disease.

175. The method according to claim 166, wherein the disease or disorder is an evaporative dry eye disease.